irblog.prnewswire.com

Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform

SOUTH SAN FRANCISCO, Calif., June 26, 2019 /PRNewswire/ -- Encoded Therapeutics, Inc. (Encoded), a precision gene therapy company, today announced a $104 million Series C financing which will be used ...
Morningstar%2c Inc.

Encoded Therapeutics Raises $275 Million in Series F Financing to Advance ETX101 Through Pivotal Development and Accelerate its Precision Genetic Medicines Neurology Pipeline

Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced the close of a $275 million ...
BIOENGINEER

mRNA-encoded antibodies show early clinical promise in cancer therapy

A Journal of Translational Medicine review outlines how mRNA-encoded antibodies, bispecific constructs, and transient CAR ...
Business Wire

Encoded Demonstrates Therapeutic Potential of a Vectorized miRNA-based Approach for Angelman Syndrome at the FAST Annual Global Science Summit

ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...
Pulse 2.0

Encoded Therapeutics Closes $135 Million In Series D Funding

Precision gene therapy company Encoded Therapeutics announced it has raised $135 million in an oversubscribed Series D round of funding Precision gene therapy company Encoded Therapeutics, Inc.
Morningstar%2c Inc.

Encoded Therapeutics Presents New Preclinical Data at ASGCT 2026 Highlighting Precision Vector Engineering Across Neurology Programs

– NociPro enables highly selective nociceptor targeting and potent NaV1.7 knockdown in rodents and non-human primates, supporting development candidate ETX301 for post‑amputation neuroma pain – – ...